Rodent-Specific Beta Amyloid Antibody

This new rodent-specific beta amyloid antibody can be a highly effective tool for identifying and measuring rodent beta amyloid.

"Increasing use of rodent models for Alzheimer's research created a critical demand for a product with rodent beta amyloid specificity,” noted Brent Dorval, Ph.D., chief technology officer of Signet Laboratories, Inc. (Dedham, MA, USA), which developed the antibody. "This antibody will serve as a valuable tool, allowing researchers to quantify the rodent beta amyloid peptide in transgenic, knockout, and wild-type models.”

Founded in 1989, Signet is a commercial spinout of Johnson & Johnson's Cambridge Research Laboratories, Inc. (CRL, Cambridge, MA. USA).







Related Links:
Signet Laboratories, Inc.